Focus: Nordic Pharma is a France-based specialty pharmaceutical company focused on diagnostics and hyaluronic acid-based products, with a concentrated revenue model centered on a single marketed drug.
Profile data last refreshed 14h ago · AI intelligence enriched 3w ago
Nordic Pharma offers niche exposure to specialty pharma but carries high execution risk due to revenue concentration and limited hiring activity; best suited for mission-driven candidates willing to accept restructuring uncertainty.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Company's only revenue-generating asset; antimetabolite MOA targeting dihydrofolate reductase for DNA synthesis inhibition in rapidly dividing cells.
Help build intelligence for Nordic Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Nordic Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Second marketed NDA approaching loss of exclusivity with no disclosed LOE date; Part D spending not reported.
1 discontinued, 0 duplicate formulations not shown
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo